Company news
MaxCyte, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
November 10, 2026
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
November 10, 2026
MaxCyte to Participate in Three Upcoming Investor Conferences
October 28, 2026
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
October 14, 2026
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
September 23, 2026
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
August 19, 2026
MaxCyte Reports Second Quarter 2026 Financial Results
August 12, 2026
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
July 21, 2026
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
July 15, 2026
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
May 12, 2026
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
April 29, 2026
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 30, 2026
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
March 23, 2026
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
March 22, 2026
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
February 24, 2026
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
February 23, 2026
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
MaxCyte Announces Planned CFO Transition in 2026
November 12, 2025
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 12, 2025
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 5, 2025
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
October 8, 2025
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
October 6, 2025
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
September 22, 2025
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
August 6, 2025
MaxCyte Signs Platform License Agreement with Adicet Bio
August 4, 2025
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
July 31, 2025
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
July 9, 2025
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan
July 1, 2025
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
June 11, 2025
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
May 7, 2025
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
April 10, 2025
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
March 11, 2025
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
February 11, 2025
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
January 29, 2025
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
January 12, 2025
MaxCyte Announces Retirement of Board Member Art Mandell
December 21, 2024
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
December 7, 2024
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
November 12, 2024
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
November 5, 2024
MaxCyte Appoints Cynthia Collins to its Board of Directors
October 14, 2024
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
October 9, 2024
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
September 14, 2024
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
August 5, 2024
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
May 21, 2024
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
May 6, 2024
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
April 9, 2024
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
April 1, 2024
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
March 11, 2024
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
March 3, 2024
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
February 8, 2024
Calls
The 5 newest of 22 calls. Every call is listed under its year.
- MaxCyte (NASDAQ:MXCT) Q3 2026 Earnings Call
Nov 10, 2026
Transcript - MaxCyte (NASDAQ:MXCT) Q2 2026 Earnings Call
Aug 12, 2026
Transcript - MaxCyte (NASDAQ:MXCT) Q1 2026 Earnings Call
May 12, 2026
Transcript - MaxCyte (NASDAQ:MXCT) Q4 2025 Earnings Call
Mar 24, 2026
Transcript - MaxCyte (NASDAQ:MXCT) Q3 2025 Earnings Call
Nov 12, 2025
Transcript
Decks
The 5 newest of 18 decks. Every deck is listed under its year.
- Investor Presentation (November 2026)
Investor deck · 29 slides · Nov 10, 2026
- Merger or Acquisition (November 2026)
Merger or acquisition · 14 slides · Nov 10, 2026
- Investor Presentation (August 2026)
Investor deck · 29 slides · Aug 12, 2026
- Q2 2026 Earnings Presentation
Earnings · 10 slides · Aug 12, 2026
- Investor Presentation (May 2026)
Investor deck · 27 slides · May 12, 2026